Harnessing the immune system to potentiate oncolytics.
作者信息
Gottschalk Stephen, Rooney Cliona M
机构信息
Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, Texas, USA.
出版信息
Mol Ther. 2014 Feb;22(2):239-240. doi: 10.1038/mt.2013.295.
Abstract
摘要
相似文献
1
Harnessing the immune system to potentiate oncolytics.利用免疫系统增强溶瘤作用。
Mol Ther. 2014 Feb;22(2):239-240. doi: 10.1038/mt.2013.295.
2
Oncolytic Immunotherapy.溶瘤免疫疗法
Surg Oncol Clin N Am. 2019 Jul;28(3):419-430. doi: 10.1016/j.soc.2019.02.007. Epub 2019 Apr 5.
3
The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon.溶瘤病毒与免疫系统的较量：等待所罗门的裁决。
Hum Gene Ther. 2009 Oct;20(10):1119-32. doi: 10.1089/hum.2009.135.
4
Oncolytic viruses: focusing on the tumor microenvironment.溶瘤病毒：聚焦肿瘤微环境
Cancer Gene Ther. 2015 Mar;22(4):169-71. doi: 10.1038/cgt.2015.11. Epub 2015 Feb 27.
5
Development of oncolytic virotherapy: from genetic modification to combination therapy.溶瘤病毒治疗的发展：从基因修饰到联合治疗。
Front Med. 2020 Apr;14(2):160-184. doi: 10.1007/s11684-020-0750-4. Epub 2020 Mar 7.
6
Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.溶瘤病毒对肿瘤微环境的免疫转换：细小病毒 H-1PV 案例研究。
Front Immunol. 2019 Aug 7;10:1848. doi: 10.3389/fimmu.2019.01848. eCollection 2019.
7
Integrating oncolytic viruses in combination cancer immunotherapy.将溶瘤病毒整合到联合癌症免疫疗法中。
Nat Rev Immunol. 2018 Aug;18(8):498-513. doi: 10.1038/s41577-018-0014-6.
8
Combining oncolytic virotherapy and tumour vaccination.联合溶瘤病毒治疗和肿瘤疫苗接种。
Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):143-8. doi: 10.1016/j.cytogfr.2010.02.009. Epub 2010 Mar 11.
9
Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies.免疫原性肿瘤细胞死亡、溶瘤病毒与免疫系统的关键相互作用决定了联合免疫疗法的合理设计。
J Immunol. 2018 Jan 15;200(2):450-458. doi: 10.4049/jimmunol.1701021.
10
Potentiating oncolytic viral therapy through an understanding of the initial immune responses to oncolytic viral infection.通过了解抗肿瘤病毒感染的初始免疫反应来增强抗肿瘤病毒治疗。
Curr Opin Virol. 2015 Aug;13:25-32. doi: 10.1016/j.coviro.2015.03.015. Epub 2015 Apr 4.
本文引用的文献
1
New viruses for cancer therapy: meeting clinical needs.新型病毒在癌症治疗中的应用：满足临床需求。
Nat Rev Microbiol. 2014 Jan;12(1):23-34. doi: 10.1038/nrmicro3140. Epub 2013 Dec 2.
2
T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy.T 细胞衔接器武装溶瘤痘病毒显著增强抗肿瘤治疗。
Mol Ther. 2014 Jan;22(1):102-11. doi: 10.1038/mt.2013.240. Epub 2013 Oct 17.
3
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.随机剂量探索性临床试验：溶瘤免疫治疗性痘苗病毒 JX-594 在肝癌中的应用。
Nat Med. 2013 Mar;19(3):329-36. doi: 10.1038/nm.3089. Epub 2013 Feb 10.
4
Oncolytic virotherapy.溶瘤病毒疗法。
Nat Biotechnol. 2012 Jul 10;30(7):658-70. doi: 10.1038/nbt.2287.
5
Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients.表达 CD40L 的复制型腺病毒治疗晚期实体瘤的溶瘤免疫疗法：评估患者的安全性和免疫应答。
Cancer Res. 2012 Apr 1;72(7):1621-31. doi: 10.1158/0008-5472.CAN-11-3001. Epub 2012 Feb 9.
6
Cell carriers for oncolytic viruses: Fed Ex for cancer therapy.肿瘤溶瘤病毒的细胞载体：癌症治疗的“联邦快递”。
Mol Ther. 2009 Oct;17(10):1667-76. doi: 10.1038/mt.2009.194. Epub 2009 Aug 18.
Zotero 插件